Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

183.61$-1.48 -0.80 %
At close       04:00 PM    

Stock Snapshot

185.09
Prev. Close
185.30
Open
48.02B
Market Cap
4.19M
Number of Shares
182.00
Day Low
185.30
Day High
183.61
24.21
P/E Ratio
-
Free Float in %
7.59
EPS 2021
35.51
Book Value per Share
25.65
Cash Flow per Share
Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals Incorporated (VRTX) stock rallied over -0.80% intraday to trade at $183.61 share on NASDAQ. The stock opened with a gain of % at $185.30 and touched an intraday high of $185.30, rising 0.11% against the last close of $185.09. The stock went to a low of $182.00 during the session.

Historical Data

DateOpenCloseDaily HighDaily LowVolume
2021-09-10$188.17$188.57$190.09$186.151,375,527
2021-09-03$198.50$198.05$199.18$196.6698,540,000
2021-09-02$198.06$199.22$199.80$196.60124,010,000
2021-09-01$200.62$197.14$202.55$196.35145,070,000
2021-08-31$200.21$200.29$200.35$198.15188,970,000
2021-08-30$199.30$199.49$201.56$198.70111,960,000
2021-08-27$198.15$199.92$202.77$195.85129,000,000
2021-08-26$200.94$198.25$202.74$197.91113,470,000
2021-08-25$199.59$201.33$202.17$198.09119,270,000
2021-08-24$198.82$199.73$200.16$196.6888,010,000
2021-08-23$197.27$198.40$200.50$196.14112,480,000
Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA 02210
United States

http://www.vrtx.com
617 341 6100
Employees
3400
Sector
Healthcare
Sales or Revenue
6.68B
Industry
Biotechnology
5Y Sales Change
43.20
Fiscal Year Ends
2020-12-30

Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam